← Back to Screener
Caris Life Sciences, Inc. Common Stock (CAI)
Price$21.24
Favorite Metrics
Price vs S&P 500 (26W)-39.36%
Price vs S&P 500 (4W)5.39%
Market Capitalization$5.98B
All Metrics
P/CF (Annual)71.87x
Book Value / Share (Quarterly)$2.04
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$0.24
Price vs S&P 500 (YTD)-25.75%
Gross Margin (TTM)66.40%
Net Profit Margin (TTM)-8.39%
EPS (TTM)$-0.25
10-Day Avg Trading Volume1.82M
EPS Excl Extra (TTM)$-0.25
EPS (Annual)$-0.41
ROI (Annual)-7.12%
Gross Margin (Annual)66.63%
Cash / Share (Quarterly)$2.83
Revenue Growth QoQ (YoY)-28.96%
ROA (Last FY)-6.05%
EBITD / Share (TTM)$0.17
Operating Margin (TTM)3.11%
Cash Flow / Share (Annual)$0.24
P/B Ratio10.35x
P/B Ratio (Quarterly)13.19x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)0.27x
ROA (TTM)-8.11%
EPS Incl Extra (Annual)$-0.41
Current Ratio (Annual)7.85x
Quick Ratio (Quarterly)7.19x
3-Month Avg Trading Volume2.39M
EV / Free Cash Flow (Annual)83.10x
Revenue / Employee (TTM)$0
P/S Ratio (Annual)7.36x
Asset Turnover (Annual)0.72x
52-Week High$42.50
EPS Excl Extra (Annual)$-0.41
26-Week Price Return-30.61%
Quick Ratio (Annual)7.19x
13-Week Price Return-19.95%
Total Debt / Equity (Annual)0.66x
Current Ratio (Quarterly)7.85x
Enterprise Value$5,559.283
Asset Turnover (TTM)0.97x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-8.38%
Cash / Share (Annual)$2.83
3-Month Return Std Dev59.40%
Net Income / Employee (TTM)$-0
ROE (Last FY)-11.79%
Net Interest Coverage (Annual)0.27x
EPS Basic Excl Extra (Annual)$-0.41
EV / Free Cash Flow (TTM)83.10x
Total Debt / Equity (Quarterly)0.66x
EPS Incl Extra (TTM)$-0.25
P/S Ratio (TTM)7.36x
Revenue / Share (Annual)$4.86
Forward P/E176.28x
Year-to-Date Return-21.61%
5-Day Price Return10.56%
EPS Normalized (Annual)$-0.41
Net Profit Margin (Annual)-8.38%
Month-to-Date Return18.29%
EBITD / Share (Annual)$0.15
Operating Margin (Annual)3.11%
LT Debt / Equity (Annual)0.66x
P/CF (TTM)71.87x
LT Debt / Equity (Quarterly)0.66x
EPS Basic Excl Extra (TTM)$-0.25
P/B Ratio (Annual)13.19x
Pretax Margin (TTM)-8.39%
Book Value / Share (Annual)$2.04
Price vs S&P 500 (13W)-22.81%
Beta0.38x
P/FCF (Annual)89.34x
Revenue / Share (TTM)$2.86
52-Week Low$16.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.23
4.29
4.29
Industry Peers — Health Services(21)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
CAICaris Life Sciences, Inc. Common Stock | — | — | 3.11% | — | $21.24 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $207.74 |
LHLabcorp Holdings Inc. | 25.31x | 7.25% | 9.92% | 10.28% | $269.19 |
DGXQuest Diagnostics Inc. | 21.75x | 11.78% | 14.10% | 13.88% | $196.31 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $91.07 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $57.85 |
VCYTVeracyte, Inc. | 39.66x | 16.01% | 11.17% | 5.33% | $33.45 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $51.20 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $21.29 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.44 |
About
Caris Life Sciences develops AI-powered molecular diagnostic solutions for oncology, enabling personalized cancer treatment decisions. The company leverages comprehensive molecular profiling and machine learning algorithms to provide physicians with precision medicine insights. Its technology platform aims to improve patient outcomes while supporting clinical and pharmaceutical decision-making.